MA22866A1 - Procede pour la preparation des composes pour le traitement des troubles neuro-degeneratifs . - Google Patents
Procede pour la preparation des composes pour le traitement des troubles neuro-degeneratifs .Info
- Publication number
- MA22866A1 MA22866A1 MA23157A MA23157A MA22866A1 MA 22866 A1 MA22866 A1 MA 22866A1 MA 23157 A MA23157 A MA 23157A MA 23157 A MA23157 A MA 23157A MA 22866 A1 MA22866 A1 MA 22866A1
- Authority
- MA
- Morocco
- Prior art keywords
- treatment
- neuro
- compounds
- preparation
- degenerative disorders
- Prior art date
Links
- 208000015122 neurodegenerative disease Diseases 0.000 title abstract 2
- 150000001875 compounds Chemical class 0.000 title 1
- 238000000034 method Methods 0.000 title 1
- FWUQWDCOOWEXRY-ZDUSSCGKSA-N lanicemine Chemical compound C([C@H](N)C=1C=CC=CC=1)C1=CC=CC=N1 FWUQWDCOOWEXRY-ZDUSSCGKSA-N 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/24—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with substituted hydrocarbon radicals attached to ring carbon atoms
- C07D213/36—Radicals substituted by singly-bound nitrogen atoms
- C07D213/38—Radicals substituted by singly-bound nitrogen atoms having only hydrogen or hydrocarbon radicals attached to the substituent nitrogen atom
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A61P21/02—Muscle relaxants, e.g. for tetanus or cramps
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
- A61P25/10—Antiepileptics; Anticonvulsants for petit-mal
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
- A61P25/12—Antiepileptics; Anticonvulsants for grand-mal
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Neurology (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Medicinal Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pain & Pain Management (AREA)
- Psychiatry (AREA)
- Psychology (AREA)
- Hospice & Palliative Care (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Physical Education & Sports Medicine (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Pyridine Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Steroid Compounds (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GB929207339A GB9207339D0 (en) | 1992-04-03 | 1992-04-03 | Pharmaceutical compound |
| GB929208290A GB9208290D0 (en) | 1992-04-15 | 1992-04-15 | Pharmaceutical compound having neuroprotective properties |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MA22866A1 true MA22866A1 (fr) | 1993-12-31 |
Family
ID=26300643
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MA23157A MA22866A1 (fr) | 1992-04-03 | 1993-04-02 | Procede pour la preparation des composes pour le traitement des troubles neuro-degeneratifs . |
Country Status (28)
| Country | Link |
|---|---|
| EP (1) | EP0633879B1 (fr) |
| JP (2) | JP3120810B2 (fr) |
| KR (1) | KR100259567B1 (fr) |
| CN (1) | CN1044367C (fr) |
| AT (1) | ATE163925T1 (fr) |
| AU (2) | AU3897693A (fr) |
| CA (1) | CA2133427C (fr) |
| CZ (1) | CZ288519B6 (fr) |
| DE (1) | DE69317411T2 (fr) |
| DK (1) | DK0633879T3 (fr) |
| DZ (1) | DZ1677A1 (fr) |
| ES (1) | ES2115055T3 (fr) |
| FI (1) | FI105025B (fr) |
| HU (1) | HU211529A9 (fr) |
| IL (1) | IL105276A (fr) |
| MA (1) | MA22866A1 (fr) |
| MX (1) | MX9301935A (fr) |
| MY (1) | MY110149A (fr) |
| NO (1) | NO302170B1 (fr) |
| NZ (1) | NZ251384A (fr) |
| PL (1) | PL180014B1 (fr) |
| RU (1) | RU2128650C1 (fr) |
| SG (1) | SG47948A1 (fr) |
| SK (1) | SK281258B6 (fr) |
| TW (1) | TW282455B (fr) |
| UA (1) | UA29437C2 (fr) |
| WO (1) | WO1993020052A1 (fr) |
| ZA (1) | ZA932415B (fr) |
Families Citing this family (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB9320273D0 (en) * | 1993-04-01 | 1993-11-17 | Fisons Corp | Compound useful in therapy |
| EP0356035B1 (fr) * | 1988-08-12 | 1996-03-13 | Astra Aktiebolag | Arylalkyl-amines et -amides à activité anticonvulsive et neuroprotectrice |
| ZA942140B (en) * | 1993-04-01 | 1994-10-03 | Fisons Corp | Salt of (S)-alpha-phenyl-2-pyridineethanamine useful in therapy |
| SE9901077D0 (sv) * | 1999-03-23 | 1999-03-23 | Astra Ab | Novel use |
| SE9901237D0 (sv) * | 1999-04-06 | 1999-04-06 | Astra Ab | Novel use |
| SE9901340D0 (sv) | 1999-04-15 | 1999-04-15 | Astra Pharma Prod | Novel process |
| MXPA02000927A (es) * | 1999-07-28 | 2003-07-14 | Johnson & Johnson | Amina y derivados de amida como ligandos para el receptor del neuropeptido y y5 utiles en el tratamiento de obesidad y otros trastornos. |
| WO2007017652A2 (fr) * | 2005-08-10 | 2007-02-15 | Astrazeneca Ab | Utilisation therapeutique |
| EP2391606A4 (fr) * | 2008-12-24 | 2012-06-13 | Astrazeneca Ab | Composés d'éthanamine et leur application pour le traitement de la dépression |
| WO2013088135A1 (fr) | 2011-12-14 | 2013-06-20 | Astrazeneca Ab | Diagnostic de gabr-a2 |
| DK3066091T3 (da) * | 2013-11-05 | 2019-07-15 | Astrazeneca Ab | Nmda-antagonist-prodrugs |
| MX2022016183A (es) * | 2020-06-23 | 2023-02-13 | Biohaven Therapeutics Ltd | Formulaciones topicas de (1s)-1-fenil-2-piridin-2-iletanamina. |
Family Cites Families (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP0320006A3 (fr) * | 1987-12-11 | 1990-12-19 | Laboratoires Syntex | Utilisations de 1,4-dihydropyridines |
| EP0356035B1 (fr) * | 1988-08-12 | 1996-03-13 | Astra Aktiebolag | Arylalkyl-amines et -amides à activité anticonvulsive et neuroprotectrice |
-
1993
- 1993-04-01 KR KR1019940703465A patent/KR100259567B1/ko not_active Expired - Lifetime
- 1993-04-01 CA CA002133427A patent/CA2133427C/fr not_active Expired - Lifetime
- 1993-04-01 PL PL93305404A patent/PL180014B1/pl unknown
- 1993-04-01 NZ NZ251384A patent/NZ251384A/en not_active IP Right Cessation
- 1993-04-01 ES ES93907975T patent/ES2115055T3/es not_active Expired - Lifetime
- 1993-04-01 RU RU94042465A patent/RU2128650C1/ru active
- 1993-04-01 AU AU38976/93A patent/AU3897693A/en not_active Abandoned
- 1993-04-01 SG SG1996005610A patent/SG47948A1/en unknown
- 1993-04-01 UA UA94095853A patent/UA29437C2/uk unknown
- 1993-04-01 EP EP93907975A patent/EP0633879B1/fr not_active Expired - Lifetime
- 1993-04-01 CZ CZ19942409A patent/CZ288519B6/cs not_active IP Right Cessation
- 1993-04-01 JP JP05517251A patent/JP3120810B2/ja not_active Expired - Lifetime
- 1993-04-01 WO PCT/GB1993/000689 patent/WO1993020052A1/fr not_active Ceased
- 1993-04-01 SK SK1177-94A patent/SK281258B6/sk not_active IP Right Cessation
- 1993-04-01 AT AT93907975T patent/ATE163925T1/de active
- 1993-04-01 DE DE69317411T patent/DE69317411T2/de not_active Expired - Lifetime
- 1993-04-01 DK DK93907975T patent/DK0633879T3/da active
- 1993-04-02 IL IL105276A patent/IL105276A/xx not_active IP Right Cessation
- 1993-04-02 MX MX9301935A patent/MX9301935A/es unknown
- 1993-04-02 ZA ZA932415A patent/ZA932415B/xx unknown
- 1993-04-02 MA MA23157A patent/MA22866A1/fr unknown
- 1993-04-02 MY MYPI93000602A patent/MY110149A/en unknown
- 1993-04-03 CN CN93104534A patent/CN1044367C/zh not_active Expired - Lifetime
- 1993-04-03 DZ DZ930038A patent/DZ1677A1/fr active
- 1993-04-30 TW TW082103364A patent/TW282455B/zh not_active IP Right Cessation
-
1994
- 1994-09-30 NO NO943645A patent/NO302170B1/no not_active IP Right Cessation
- 1994-09-30 FI FI944546A patent/FI105025B/fi not_active IP Right Cessation
-
1995
- 1995-06-13 HU HU95P/P00192P patent/HU211529A9/hu unknown
-
1996
- 1996-12-18 AU AU75456/96A patent/AU705419B2/en not_active Expired
-
2000
- 2000-05-30 JP JP2000159319A patent/JP2000319259A/ja active Pending
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| EG20218A (en) | Process for preparing of substituted 3 aminoquinuclidines | |
| EP0668750A4 (fr) | Vis pediculaire et appareillage de correction de la colonne par l'approche posterieure. | |
| MA22626A1 (fr) | Procede de preparation d'acides imidazolyl-alcenoiques . | |
| FR2690855B1 (fr) | Adsorbants pour l'elimination de hcl et procede pour leur production et leur utilisation. | |
| MA26410A1 (fr) | Formulations pharmaceutiques et procede pour leur production. | |
| BG101118A (en) | Therapeutical compounds | |
| FR2740132B1 (fr) | Procede pour la preparation de 1,1,1,3,3-pentafluoropropane | |
| MA22866A1 (fr) | Procede pour la preparation des composes pour le traitement des troubles neuro-degeneratifs . | |
| EP0673384A4 (fr) | Polypeptides utiles pour traiter des troubles inflammatoires. | |
| FR2705966B1 (fr) | Compositions antimousse utiles notamment pour le traitement de troubles gastriques. | |
| MA23134A1 (fr) | Procede pour la preparation d'aryl-piperidine carbinols . | |
| CA2217513A1 (fr) | Agents pharmaceutiques pour le traitement de la maladie d'alzheimer | |
| MA23663A1 (fr) | Procede de preparation de formulations pharmaceutiques | |
| MA22278A1 (fr) | Procede pour le traitement de troubles respiratoires | |
| FR2700956B1 (fr) | Composition cosmetique et pharmaceutique et procede pour sa preparation. | |
| FR2733227B1 (fr) | Procede pour la preparation de 1,1-difluoroethane | |
| MA23081A1 (fr) | Procede de preparation de derives d'indolone | |
| MA23953A1 (fr) | Procede nouveau pour formuler des formes posologiques solides, et formes posologiques ainsi produites | |
| FR2677354B1 (fr) | Procede pour la preparation d'esters d'acides racemisables. | |
| IL99236A0 (en) | Pharmaceutical composition for the topical treatment of psoriasis | |
| FR2673635B1 (fr) | Procede pour la preparation d'une composition aerosol. | |
| FR2736635B1 (fr) | Procede de preparation d'alpha,omega-bromochloroalcanes | |
| FR2696171B1 (fr) | Procede de preparation du divinylbenzene. | |
| FR2676583B1 (fr) | Procede pour la desorption d'iode de fission. | |
| FR2702769B1 (fr) | Nouveau procede de preparation d'alkylpolyosides faiblement colores. |